Capricor Therapeutics, Inc. - Common Stock (CAPR)

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc.  (“Capricor” or the “Company”) (NASDAQ: CAPR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK - July 28, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a class action securities lawsuit.

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) between October 9, 2024 and July 10, 2025, inclusive.

SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between October 9, 2024 and July 10, 2025. Capricor is a clinical-stage biotechnology company that engages in the development of transformative cell and exosome-based therapeutics for treating

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Capricor To Contact Him Directly To Discuss Their Options

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK - July 25, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a class action securities lawsuit.

If you purchased or acquired securities in any of the above companies during their class period and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK - July 24, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a class action securities lawsuit.

NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc.  (“Capricor” or the “Company”) (NASDAQ: CAPR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK - July 23, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a class action securities lawsuit.

The DJS Law Group reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. (“Capricor” or “the Company”) (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK - July 22, 2025 ( NEWMEDIAWIRE ) - Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (“Capricor” or “the Company”) (NASDAQ: CAPR) and certain of its officers.

NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) --

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK - July 22, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a class action securities lawsuit.

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between October 9, 2024 and July 10, 2025, both dates inclusive (the “Class Period”). Capricor is a clinical-stage biotechnology company.

Gibbs Mura announces that a class action lawsuit was filed against Capricor Therapeutics, Inc. on behalf of investors who purchased or acquired Capricor securities between October 9, 2024 and July 10, 2025. Shares of Capricor plunged over 30% in intraday trading on Friday, July 11, 2025, after the U.S. Food and Drug Administration rejected the company’s Biologics License Application for its lead cell therapy candidate, Deramiocel, claiming that the application “does not meet the statutory requirement for substantial evidence of effectiveness” and lacks “certain outstanding items.” Gibbs Mura encourages investors to contact us about their legal rights and options in the Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Class Action Lawsuit.

PHILADELPHIA, July 21, 2025 (GLOBE NEWSWIRE) --

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK - July 21, 2025 ( NEWMEDIAWIRE ) Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a class action securities lawsuit.